On Friday, the Vetr crowd upgraded their rating for
Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY)
from its previous position at 1 star (Strong Sell) issued 88 days ago, to 4.5 star (Strong Buy). Crowd sentiment for the stock is
edging positive with 66 percent of Vetr user ratings bullish.
The massive upgrade for Alnylam arrives on the same day the company announced it would livestream its R&D day press
conference to investors. At the recent American Society of Hematology meeting in San Diego, the company revealed positive results
in early tests of fitusiran, an experimental drug used to treat the effects of hemophilia.
Share price in Anylam enjoyed a healthy 6.6 percent jump early in the trading day on December 9. By 2 p.m. that same day, the
stock had settled at $42.25.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $49.75, which is still far below the average analyst
price of $70.13. Less than 2 percent of Vetr users are holding ALNY in their watch-lists.
At last check, Alnylam shares were up 3.54 percent at $42.25.
Latest Ratings for ALNY
| Date |
Firm |
Action |
From |
To |
| Oct 2016 |
Morgan Stanley |
Downgrades |
Overweight |
Equal-weight |
| Oct 2016 |
Stifel Nicolaus |
Maintains |
|
Hold |
| Oct 2016 |
Goldman Sachs |
Maintains |
|
Neutral |
View More Analyst Ratings for
ALNY
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.